WO2005115365A2 - Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent - Google Patents
Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent Download PDFInfo
- Publication number
- WO2005115365A2 WO2005115365A2 PCT/FR2005/001211 FR2005001211W WO2005115365A2 WO 2005115365 A2 WO2005115365 A2 WO 2005115365A2 FR 2005001211 W FR2005001211 W FR 2005001211W WO 2005115365 A2 WO2005115365 A2 WO 2005115365A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- depigmenting
- mequinol
- skin
- depigmenting agent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 239000007854 depigmenting agent Substances 0.000 title claims abstract description 20
- 239000002537 cosmetic Substances 0.000 title claims abstract description 18
- 229960003505 mequinol Drugs 0.000 title claims abstract description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 8
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 8
- 208000003351 Melanosis Diseases 0.000 claims description 6
- 208000012641 Pigmentation disease Diseases 0.000 claims description 6
- 206010008570 Chloasma Diseases 0.000 claims description 5
- 230000000475 sunscreen effect Effects 0.000 claims description 5
- 239000000516 sunscreening agent Substances 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229960000271 arbutin Drugs 0.000 claims description 4
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004705 kojic acid Drugs 0.000 claims description 4
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 210000003491 skin Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- HEAHZSUCFKFERC-LRVMPXQBSA-N [(2e)-2-[[4-[(z)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-LRVMPXQBSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003747 ecamsule Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the present invention relates to a new cosmetic or dermatological composition
- a new cosmetic or dermatological composition comprising in combination mequinol (or 4-hydroxyanisole) and a depigmenting agent usable by topical application for depigmentation of the skin.
- the composition according to the invention may also contain a sunscreen.
- the pigmentation of the skin results from the synthesis of melanin in the melanocytes of the dermis by the transformation of tyrosine under the influence of a cuproprotein enzyme tyrosinase.
- Mequinol or 4-hydroxyanisole has long been known as a compound having depigmenting activity (Brun R, Journal of the society of cosmetic chemists (1960), 11, 571-9).
- mequinol as a depigmenting agent is to act as a substrate for tyrosinase (Riley P, Journal of Pathology (1969), 97 (2) 1 185-91 and Journal of Pathology (1969), 97 ( 2), 193-206.
- Vitamin C or its derivatives are usually used as antioxidants at concentrations lower than 0.005% of the entire composition, as illustrated in US patent 6,353,029.
- Kojic acid is already known in the prior art as a fungal metabolic with antioxidant properties, which causes contact dermatitis when its use is prolonged.
- Azelaic acid has been reported in the literature as effective in the treatment of melasma, but this activity seems controversial (Sarkar et al., Dermatology 2002, 205: 249-254).
- the invention therefore relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol and at least one depigmenting agent chosen from the list consisting of kojic acid and its derivatives; azelaic acid and its derivatives; dicarboxylic acids; vitamin C and its derivatives, arbutin and its derivatives and paracetamol.
- the depigmenting composition of the skin may comprise, as depigmenting agent kojic acid, azelaic acid or arbutin.
- physiologically acceptable medium means a medium compatible with the skin, the mucous membranes and / or the integuments.
- depigmenting agent means any active agent having a depigmenting activity on the skin. This activity makes it possible to decrease the already existing pigmentation of the skin and also to prevent any additional pigmentation greater than natural pigmentation.
- composition comprising the combination according to the invention makes it possible to obtain a clear whitening of the skin.
- the invention also relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol, at least one depigmenting agent and at least one sunscreen.
- the composition according to the invention advantageously comprises between 0.0001 and 20% by weight of mequinol relative to the total weight of the composition and between 0.025 and 20% by weight of depigmenting agent relative to the total weight of the composition, and preferably, respectively, between 0.001 and 10% by weight of mequinol relative to the total weight of the composition and between 0.05 and 10% by weight of depigmenting agent relative to the total weight of the composition.
- the composition can also comprise at least one sunscreen in preferential concentrations ranging from 0.001 to 30.00% by weight relative to the total weight of the composition.
- sun filters non-limiting examples that may be mentioned include physical sun filters such as titanium dioxide, zinc oxide and chemical sun filters such as octocrylene, ethylhexyl methoxycinnamate, octyl salicylate, avobenzone, oxybenzone, ecamsule or drometrizole trisiloxane, or mixtures thereof.
- physical sun filters such as titanium dioxide, zinc oxide
- chemical sun filters such as octocrylene, ethylhexyl methoxycinnamate, octyl salicylate, avobenzone, oxybenzone, ecamsule or drometrizole trisiloxane, or mixtures thereof.
- the composition may include several sun filters.
- each sunscreen can be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
- compositions according to the invention may also comprise any additive usually used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin.
- any additive usually used in the cosmetic or pharmaceutical field such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin.
- any additive usually used in the cosmetic or pharmaceutical field such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfume
- additives can be present in the composition in an amount of 0.001 to 20% by weight relative to the total weight of the composition.
- the present invention also relates to a pharmaceutical composition as described above as a medicament.
- the present invention also relates to a cosmetic composition.
- compositions containing the combination according to the invention can have all the dosage forms normally used for topical application, for example in the form of solutions, gels, dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of soft, semi-solid or solid consistency of cream or gel type, or else microemulsions, microcapsules, microparticles or vesicular dispersions of ionic and / or nonionic type.
- These compositions are prepared according to the usual methods.
- the cosmetic or dermatological compositions of the invention may contain adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and ⁇ -hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters.
- adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and ⁇ -hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters.
- the amounts of these various adjuvants are those conventionally used in the cosmetic and / or dermatological fields, and for example from 0.01% to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles.
- the invention also relates to the use of the composition according to the invention as described above in the pharmaceutical and cosmetic field.
- compositions of the invention are particularly suitable for the treatment and prevention of pigmentation disorders.
- the compositions of the invention are suitable for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations due to abrasion. , a burn, a scar, a dermatosis, a contact allergy; nevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug origin, melanomas or any other hyperpigmentary lesions in particular those induced by photo induced or chronological aging of the skin and integuments.
- compositions according to the invention are suitable for the treatment of melasma.
- the compositions according to the invention also find an application in the cosmetic field, in particular in protection against the harmful aspects of the sun, in particular against pigmentary spots.
- the invention also relates to a non-therapeutic cosmetic treatment process for beautifying the skin and / or improving its surface appearance, characterized in that a composition is applied to the skin and / or its integuments comprising mequinol and at least one depigmenting agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent in a physiologically acceptable medium. The invention also relates to the use thereof.
Description
COMPOSITION PHARMACEUTIQUE OU COSMETIQUE COMPRENANT DU MEQUINOL ET AU MOINS UN AGENT DEPIGMENTANT PHARMACEUTICAL OR COSMETIC COMPOSITION COMPRISING MEQUINOL AND AT LEAST ONE DEPIGMENTANT AGENT
La présente invention concerne une nouvelle composition cosmétique ou dermatologique comprenant en association le mequinol (ou 4-hydroxyanisole) et un dépigmentant utilisable par application topique pour la dépigmentation de la peau. La composition selon l'invention peut également contenir un filtre solaire.The present invention relates to a new cosmetic or dermatological composition comprising in combination mequinol (or 4-hydroxyanisole) and a depigmenting agent usable by topical application for depigmentation of the skin. The composition according to the invention may also contain a sunscreen.
La pigmentation de la peau résulte de la synthèse de la mélanine dans les mélanocytes du derme par la transformation de la tyrosine sous l'influence d'une enzyme cupro- protéique la tyrosinase.The pigmentation of the skin results from the synthesis of melanin in the melanocytes of the dermis by the transformation of tyrosine under the influence of a cuproprotein enzyme tyrosinase.
On peut donc obtenir un effet de dépigmentation de la peau en utilisant un composé qui dégrade la mélanine ou un inhibiteur de la tyrosinase qui bloque le mécanisme de transformation de la tyrosine en mélanine.We can therefore obtain a depigmentation effect on the skin by using a compound which degrades melanin or a tyrosinase inhibitor which blocks the mechanism of transformation of tyrosine into melanin.
Le mequinol ou 4-hydroxyanisole est connu de longue date comme étant un composé ayant une activité dépigmentant (Brun R, Journal of the society of cosmetic chemists (1960), 11 , 571-9).Mequinol or 4-hydroxyanisole has long been known as a compound having depigmenting activity (Brun R, Journal of the society of cosmetic chemists (1960), 11, 571-9).
Le mode d'action du mequinol en tant que dépigmentant est d'agir comme un substrat de la tyrosinase (Riley P, Journal of Pathology (1969), 97(2)1 185-91 et Journal of Pathology (1969), 97(2), 193-206.The mode of action of mequinol as a depigmenting agent is to act as a substrate for tyrosinase (Riley P, Journal of Pathology (1969), 97 (2) 1 185-91 and Journal of Pathology (1969), 97 ( 2), 193-206.
La vitamine C ou ses dérivés sont habituellement utilisés comme agents antioxydants à des concentrations inférieures à 0.005% de la totalité de la composition, comme illustré dans le brevet US 6,353,029.Vitamin C or its derivatives are usually used as antioxidants at concentrations lower than 0.005% of the entire composition, as illustrated in US patent 6,353,029.
L'acide kojique est déjà connu dans l'art antérieur comme un métabolique fongique ayant des propriétés antioxydantes, et qui provoque des dermatites de contact lorsque que son utilisation est prolongée.Kojic acid is already known in the prior art as a fungal metabolic with antioxidant properties, which causes contact dermatitis when its use is prolonged.
L'acide azélaïque a été rapporté dans la littérature comme efficace dans le traitement du mélasma mais cette activité semble controversée (Sarkar et al., Dermatology 2002, 205 :249-254).Azelaic acid has been reported in the literature as effective in the treatment of melasma, but this activity seems controversial (Sarkar et al., Dermatology 2002, 205: 249-254).
La Demanderesse a découvert de manière surprenante que la combinaison du mequinol et d'un agent dépigmentant pris dans une liste précise permettait par effet de synergie
d'obtenir une réponse dépigmentante beaucoup plus efficace que celle obtenue avec le mequinol seul et ce avec des doses nettement plus faible.The Applicant has surprisingly discovered that the combination of mequinol and a depigmenting agent taken from a precise list makes it possible by synergistic effect to obtain a much more effective depigmenting response than that obtained with mequinol alone and this with significantly lower doses.
Ces quantités moindre permettront en outre de diminuer de manière significative les effets secondaires néfastes (rougeurs, irritations) liés à l'utilisation d'un dépigmentant.These lower amounts will also significantly reduce the harmful side effects (redness, irritation) associated with the use of a depigmenting agent.
L'invention se rapporte donc à une composition dépigmentante de la peau comprenant dans un milieu physiologiquement acceptable, du mequinol et au moins un agent dépigmentant choisi parmi la liste constituée par l'acide kojique et ses dérivés ; l'acide azélaique et ses dérivés ; les acides dicarboxyliques ; la vitamine C et ses dérivés, l'arbutine et ses dérivés et le paracétamol.The invention therefore relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol and at least one depigmenting agent chosen from the list consisting of kojic acid and its derivatives; azelaic acid and its derivatives; dicarboxylic acids; vitamin C and its derivatives, arbutin and its derivatives and paracetamol.
En particulier, la composition dépigmentante de la peau pourra comprendre, comme agent dépigmentant l'acide kojique, l'acide azélaique ou l'arbutine.In particular, the depigmenting composition of the skin may comprise, as depigmenting agent kojic acid, azelaic acid or arbutin.
On entend par milieu physiologiquement acceptable, un milieu compatible avec la peau, les muqueuses et/ou les phanères.The term “physiologically acceptable medium” means a medium compatible with the skin, the mucous membranes and / or the integuments.
Par agent dépigmentant, on entend tout agent actif ayant une activité dépigmentante de la peau. Cette activité permet de diminuer la pigmentation déjà existante de la peau et également d'empêcher toute pigmentation supplémentaire supérieure à la pigmentation naturelle.The term “depigmenting agent” means any active agent having a depigmenting activity on the skin. This activity makes it possible to decrease the already existing pigmentation of the skin and also to prevent any additional pigmentation greater than natural pigmentation.
L'application d'une composition comprenant l'association selon l'invention permet d'obtenir un net blanchiment de la peau.The application of a composition comprising the combination according to the invention makes it possible to obtain a clear whitening of the skin.
L'invention se rapporte aussi à une composition dépigmentante de la peau comprenant dans un milieu physiologiquement acceptable, du mequinol, au moins un agent dépigmentant et au moins un filtre solaire.The invention also relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol, at least one depigmenting agent and at least one sunscreen.
La composition selon l'invention comprend avantageusement entre 0,0001 et 20 % en poids de mequinol par rapport au poids total de la composition et entre 0.025 et 20 % en poids d'agent dépigmentant par rapport au poids total de la composition, et de préférence, respectivement, entre 0,001 et 10 % en poids de mequinol par rapport au poids total de la composition et entre 0,05 et 10 % en poids d'agent dépigmentant par rapport au poids total de la composition.
La composition peut également comprendre au moins un filtre solaire dans des concentrations préférentielles allant de 0.001 à 30.00 % en poids par rapport au poids total de la composition. Parmi les filtres solaires, on peut citer à titre d'exemple non limitatif, les filtre solaires physiques tels que le dioxyde de titane, l'oxyde de zinc et les filtres solaires chimiques tels que l'octocrylene, l'ethylhexyl methoxycinnamate, l'octyl salicylate, l'avobenzone, l'oxybenzone, l'ecamsule ou le drometrizole trisiloxane, ou leurs mélanges.The composition according to the invention advantageously comprises between 0.0001 and 20% by weight of mequinol relative to the total weight of the composition and between 0.025 and 20% by weight of depigmenting agent relative to the total weight of the composition, and preferably, respectively, between 0.001 and 10% by weight of mequinol relative to the total weight of the composition and between 0.05 and 10% by weight of depigmenting agent relative to the total weight of the composition. The composition can also comprise at least one sunscreen in preferential concentrations ranging from 0.001 to 30.00% by weight relative to the total weight of the composition. Among the sun filters, non-limiting examples that may be mentioned include physical sun filters such as titanium dioxide, zinc oxide and chemical sun filters such as octocrylene, ethylhexyl methoxycinnamate, octyl salicylate, avobenzone, oxybenzone, ecamsule or drometrizole trisiloxane, or mixtures thereof.
Dans une variante de réalisation de la présente invention, la composition pourra comprendre plusieurs filtres solaires. Auquel cas, chaque filtre solaire pourra être ajouté à une concentration allant de 0.001 à 20% en poids par rapport au poids total de la composition.In an alternative embodiment of the present invention, the composition may include several sun filters. In which case, each sunscreen can be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
Les compositions selon l'invention peuvent comprendre en outre tout additif usuellement utilisé dans le domaine cosmétique ou pharmaceutique, tel que des séquestrants, des antioxydants, des conservateurs, des charges, des électrolytes, des humectants, des colorants, de bases ou d'acides usuels, minéraux ou organiques, des parfums, des huiles essentielles, des actifs cosmétiques, des hydratants, des vitamines, des acides gras essentiels, des sphingolipides, des composés autobronzants, des agents apaisants et protecteurs de la peau. Bien entendu l'homme du métier veillera à choisir ce ou ces éventuels composés complémentaires, et/ou leur quantité, de manière telle que les propriétés avantageuses de la composition selon l'invention ne soient pas, ou substantiellement pas, altérées.The compositions according to the invention may also comprise any additive usually used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin. Of course, a person skilled in the art will take care to choose this or these optional additional compounds, and / or their quantity, in such a way that the advantageous properties of the composition according to the invention are not, or not substantially, altered.
Ces additifs peuvent être présents dans la composition à raison de 0,001 à 20 % en poids par rapport au poids total de la composition.These additives can be present in the composition in an amount of 0.001 to 20% by weight relative to the total weight of the composition.
La présente invention a aussi pour objet une composition pharmaceutique telle que décrite précédemment à titre de médicament.The present invention also relates to a pharmaceutical composition as described above as a medicament.
La présente invention a également pour objet une composition cosmétique.The present invention also relates to a cosmetic composition.
Les compositions contenant l'association selon l'invention peuvent présenter toutes les formes galeniques normalement utilisées pour une application topique, par exemple sous forme de solutions, de gels, de dispersions du type lotion ou sérum, d'émulsions de
consistance liquide ou semi-liquide du type lait, obtenues par dispersion d'une phase grasse dans une phase aqueuse (H/E) ou inversement (E/H), ou de suspensions ou émulsions de consistance molle, semi-solide ou solide du type crème ou gel, ou encore de microémulsions, de microcapsules, de microparticules ou de dispersions vésiculaires de type ionique et/ou non ionique. Ces compositions sont préparées selon les méthodes usuelles.The compositions containing the combination according to the invention can have all the dosage forms normally used for topical application, for example in the form of solutions, gels, dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of soft, semi-solid or solid consistency of cream or gel type, or else microemulsions, microcapsules, microparticles or vesicular dispersions of ionic and / or nonionic type. These compositions are prepared according to the usual methods.
De façon connue, les compositions cosmétiques ou dermatologiques de l'invention peuvent contenir des adjuvants habituels dans le domaine cosmétique ou dermatologique, tels que les emulsionnants, les gélifiants hydrophiles ou lipophiles, les actifs hydrophiles ou lipophiles différents de l'oxyde de titane et de l'α-hydroxyacide, les conservateurs, les antioxydants, les parfums, les charges, les filtres et les matières colorantes. Les quantités de ces différents adjuvants sont celles classiquement utilisées dans les domaines cosmétique et/ou dermatologique, et par exemple de 0,01 % à 20 % du poids total de la composition. Ces adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse et/ou dans les vésicules lipidiques.In known manner, the cosmetic or dermatological compositions of the invention may contain adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and α-hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters. The amounts of these various adjuvants are those conventionally used in the cosmetic and / or dermatological fields, and for example from 0.01% to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles.
L'invention se rapporte également à l'utilisation de la composition selon l'invention telle que décrite précédemment dans le domaine pharmaceutique et cosmétique.The invention also relates to the use of the composition according to the invention as described above in the pharmaceutical and cosmetic field.
Les compositions de l'invention conviennent particulièrement bien au traitement et à la prévention des désordres de la pigmentation. Préférentiellement, les compositions de l'invention conviennent au traitement et à la prévention des désordres hyperpigmentaires tels que le melasma, le chloasma, les lentigines, le lentigo sénile, le vitiligo, les taches de rousseur, les hyperpigmentations post-inflammatoires dues à une abrasion, une brûlure, une cicatrice, une dermatose, une allergie de contact; les nevi, les hyperpigmentations à déterminisme génétique, les hyperpigmentations d'origine métabolique ou médicamenteuse, les mélanomes ou toutes autres lésions hyperpigmentaires notamment celles induites par le vieillissement photo induit ou chronologique de la peau et des phanères.The compositions of the invention are particularly suitable for the treatment and prevention of pigmentation disorders. Preferably, the compositions of the invention are suitable for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations due to abrasion. , a burn, a scar, a dermatosis, a contact allergy; nevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug origin, melanomas or any other hyperpigmentary lesions in particular those induced by photo induced or chronological aging of the skin and integuments.
Plus préférentiellement les compositions selon l'invention conviennent au traitement du mélasma.
Les compositions selon l'invention trouvent également une application dans le domaine cosmétique, en particulier dans la protection contre les aspects néfastes du soleil, en particulier contre les taches pigmentaires.More preferably, the compositions according to the invention are suitable for the treatment of melasma. The compositions according to the invention also find an application in the cosmetic field, in particular in protection against the harmful aspects of the sun, in particular against pigmentary spots.
L'invention porte également sur un procédé de traitement cosmétique non thérapeutique d'embellissement de la peau et/ou d'amélioration de son aspect de surface, caractérisé par le fait que l'on applique sur la peau et/ou ses phanères une composition comprenant du mequinol et au moins un agent dépigmentant.The invention also relates to a non-therapeutic cosmetic treatment process for beautifying the skin and / or improving its surface appearance, characterized in that a composition is applied to the skin and / or its integuments comprising mequinol and at least one depigmenting agent.
Les exemples de formulations ci-dessous permettent d'illustrer les compositions selon l'invention, sans toutefois en limiter la portée. Des exemples illustrant l'activité dépigmentante des différentes compositions selon l'invention, sont également décrits.The examples of formulations below make it possible to illustrate the compositions according to the invention, without however limiting their scope. Examples illustrating the depigmenting activity of the various compositions according to the invention are also described.
Dans les compositions ci-après (exemples 1 à 6), les proportions des différents constituants sont exprimées en pourcentage en poids par rapport au poids total de la composition.In the compositions below (examples 1 to 6), the proportions of the various constituents are expressed as a percentage by weight relative to the total weight of the composition.
Exemple 1 :Example 1:
Exemple 3Example 3
Exemple 4 :Example 4:
Exemple 5 :Example 5:
Claims
1. Composition dépigmentante de la peau comprenant, dans un véhicule physiologiquement acceptable, du mequinol et au moins un agent dépigmentant choisi dans la liste constituée par l'acide kojique et ses dérivés ; l'acide azélaique et ses dérivés ; les acides dicarboxyliques ; la vitamine C et ses dérivés, l'arbutine et ses dérivés et le paracetamol.1. Skin depigmenting composition comprising, in a physiologically acceptable vehicle, mequinol and at least one depigmenting agent chosen from the list consisting of kojic acid and its derivatives; azelaic acid and its derivatives; dicarboxylic acids; vitamin C and its derivatives, arbutin and its derivatives and paracetamol.
2. Composition selon la revendication 1 , caractérisée en ce que l'agent dépigmentant est l'arbutine, le paracetamol ou la vitamine C.2. Composition according to claim 1, characterized in that the depigmenting agent is arbutin, paracetamol or vitamin C.
3. Composition selon l'une quelconque des revendications de 1 à 2, caractérisée en ce qu'elle contient également au moins un filtre solaire.3. Composition according to any one of claims 1 to 2, characterized in that it also contains at least one sunscreen.
4. Composition selon l'une quelconque des revendications de 1 à 3 à titre de médicament.4. Composition according to any one of claims 1 to 3 as a medicament.
5. Composition selon d'une quelconque des revendications 1 à 3 caractérisé en ce que la composition est une composition cosmétique.5. Composition according to any one of claims 1 to 3 characterized in that the composition is a cosmetic composition.
Utilisation d'une composition dépigmentante de la peau, comprenant du mequinol et au moins un agent dépigmentant dans un véhicule physiologiquement acceptable pour la fabrication d'une préparation pharmaceutique destinée à prévenir ou à traiter des désordres de la pigmentation.Use of a depigmenting composition for the skin, comprising mequinol and at least one depigmenting agent in a physiologically acceptable vehicle for the manufacture of a pharmaceutical preparation intended for preventing or treating pigmentation disorders.
Utilisation d'une composition selon la revendication 6 pour la fabrication d'une préparation pharmaceutique destinée à prévenir ou à traiter le melasma.Use of a composition according to claim 6 for the manufacture of a pharmaceutical preparation intended for preventing or treating melasma.
8. Utilisation cosmétique d'une composition dépigmentante de la peau, comprenant du mequinol et au moins un agent dépigmentant dans un véhicule physiologiquement acceptable, pour la protection contre les aspects néfastes du soleil.8. Cosmetic use of a depigmenting composition for the skin, comprising mequinol and at least one depigmenting agent in a physiologically acceptable vehicle, for protection against the harmful aspects of the sun.
9. utilisation cosmétique d'une composition dépigmentante de la peau, comprenant du mequinol et au moins un agent dépigmentant dans un véhicule physiologiquement acceptable comme agent de blanchiment de la peau. 9. cosmetic use of a skin depigmenting composition, comprising mequinol and at least one depigmenting agent in a physiologically acceptable vehicle as skin whitening agent.
0. Procédé de traitement cosmétique non thérapeutique d'embellissement de la peau et/ou d'amélioration de son aspect de surface, caractérisé par le fait que l'on applique sur la peau et/ou ses phanères une composition comprenant du mequinol et au moins un agent dépigmentant. 0. A non-therapeutic cosmetic treatment process for beautifying the skin and / or improving its surface appearance, characterized in that a composition comprising mequinol and at least one is applied to the skin and / or its integuments. minus a depigmenting agent.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05771145A EP1755541A2 (en) | 2004-05-14 | 2005-05-13 | Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent |
| JP2007512291A JP2007537216A (en) | 2004-05-14 | 2005-05-13 | Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent |
| CA002564104A CA2564104A1 (en) | 2004-05-14 | 2005-05-13 | Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent |
| US11/596,356 US20080159969A1 (en) | 2004-05-14 | 2005-05-13 | Pharmaceutical Or Cosmetic Composition Comprising Mequinol And At Least One Depigmenting Agent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0405280A FR2870122A1 (en) | 2004-05-14 | 2004-05-14 | PHARMACEUTICAL OR COSMETIC COMPOSITION COMPRISING MEQUINOL AND AT LEAST ONE DEPIGMENTING AGENT |
| FR0405280 | 2004-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005115365A2 true WO2005115365A2 (en) | 2005-12-08 |
| WO2005115365A3 WO2005115365A3 (en) | 2006-06-01 |
Family
ID=34945899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2005/001211 WO2005115365A2 (en) | 2004-05-14 | 2005-05-13 | Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080159969A1 (en) |
| EP (1) | EP1755541A2 (en) |
| JP (1) | JP2007537216A (en) |
| CA (1) | CA2564104A1 (en) |
| FR (1) | FR2870122A1 (en) |
| WO (1) | WO2005115365A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006037958A2 (en) * | 2004-10-01 | 2006-04-13 | Cambridge Enterprise Limited | Treatment of helminth infection by inhibition of tyrosinase |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101938974A (en) * | 2007-11-14 | 2011-01-05 | Omp有限公司 | Skin treatment compositions |
| FR2984730A1 (en) * | 2011-12-22 | 2013-06-28 | Diverchim | NEW ANTI-AGE AND DEPIGMENTING COSMETIC COMPOSITIONS |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164185A (en) * | 1989-10-20 | 1992-11-17 | L'oreal | Pharmaceutical and cosmetic depigmentation compositions with a caffeic acid base |
| US5561157A (en) * | 1986-12-23 | 1996-10-01 | Tristrata Inc | Method for enhancing the therapeutic effect of a composition comprising hydroquinone and comprising same |
| US6710076B2 (en) * | 1994-10-24 | 2004-03-23 | Physician's Choice Of Arizona, Inc. | Hydroxy-kojic acid skin peel |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6353029B1 (en) * | 2000-08-24 | 2002-03-05 | Bristol-Myers Squibb Company | Storage stable tretinoin and 4-hydroxyanisole containing topical composition |
| US20040028642A1 (en) * | 2002-04-26 | 2004-02-12 | Isabelle Hansenne | Cosmetic composition comprising an extract of emblica officinalis and methods of using same |
-
2004
- 2004-05-14 FR FR0405280A patent/FR2870122A1/en active Pending
-
2005
- 2005-05-13 US US11/596,356 patent/US20080159969A1/en not_active Abandoned
- 2005-05-13 EP EP05771145A patent/EP1755541A2/en not_active Withdrawn
- 2005-05-13 CA CA002564104A patent/CA2564104A1/en not_active Abandoned
- 2005-05-13 WO PCT/FR2005/001211 patent/WO2005115365A2/en active Application Filing
- 2005-05-13 JP JP2007512291A patent/JP2007537216A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561157A (en) * | 1986-12-23 | 1996-10-01 | Tristrata Inc | Method for enhancing the therapeutic effect of a composition comprising hydroquinone and comprising same |
| US5164185A (en) * | 1989-10-20 | 1992-11-17 | L'oreal | Pharmaceutical and cosmetic depigmentation compositions with a caffeic acid base |
| US6710076B2 (en) * | 1994-10-24 | 2004-03-23 | Physician's Choice Of Arizona, Inc. | Hydroxy-kojic acid skin peel |
Non-Patent Citations (2)
| Title |
|---|
| BRIGANTI S ET AL: "Chemical and Instrumental Approaches to Treat Hyperpigmentation (Review: Innovative Technology)" PIGMENT CELL RESEARCH, MUNKSGAARD INTERNATIONAL PUBLISHERS, CAMBRIDGE, MA, DK, vol. 16, 2003, pages 101-110, XP002262229 ISSN: 0893-5785 * |
| KATSAMBAS ET AL.: "Depigmenting and Bleaching Agents: Coping with Hyperpigmentation" CLINICS IN DERMATOLOGY, vol. 19, 2001, pages 483-488, XP002310205 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006037958A2 (en) * | 2004-10-01 | 2006-04-13 | Cambridge Enterprise Limited | Treatment of helminth infection by inhibition of tyrosinase |
| WO2006037958A3 (en) * | 2004-10-01 | 2006-07-27 | Univ Cambridge Tech | Treatment of helminth infection by inhibition of tyrosinase |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2564104A1 (en) | 2005-12-08 |
| US20080159969A1 (en) | 2008-07-03 |
| FR2870122A1 (en) | 2005-11-18 |
| WO2005115365A3 (en) | 2006-06-01 |
| EP1755541A2 (en) | 2007-02-28 |
| JP2007537216A (en) | 2007-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0780115B1 (en) | Nanoparticles coated with a lamellar phase based on a silicone surfactant and compositions containing them | |
| EP0661038B1 (en) | Depigmentation composition for the simultaneous treatment of the superficial skinlayers and the deep skinlayers | |
| FR2956818A1 (en) | Cosmetic use of peptide hydrolyzate from flax (Linum kind), as active agent in composition to soothe the skin, to prevent the damage or restore the skin barrier function and for preventing or treating skin inflammations e.g. reddening | |
| CA2685482A1 (en) | Dermatological and cosmetic depigmenting compositions, methods for the preparation thereof and uses thereof | |
| FR2798590A1 (en) | USE OF ALVERINE TO REDUCE WRINKLES | |
| WO2018142033A1 (en) | Depigmenting dermatological and cosmetic compositions | |
| CA2568262A1 (en) | Hydroalcoholic depigmentation gel comprising mequinol and adapalene | |
| FR2849597A1 (en) | Cosmetic composition for treating greasy skin, contains a dicarboxylic fatty acid or derivative, reduces secretion of sebum and inhibits lipogenesis | |
| CA2561393A1 (en) | Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent | |
| WO2010146294A1 (en) | Plant extract for preparing a composition for controlling melanogenesis, resulting control composition, and control method implementing such a composition | |
| FR2883752A1 (en) | USE OF COMPOUNDS INDUCING THE SYNTHESIS OF SIRT PROTEINS IN OR FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION | |
| FR2885050A1 (en) | Slimming cosmetic and/or pharmaceutical composition, useful for treatment of adipocytes of skin, comprises cocoa extract containing polyphenols | |
| WO2005115365A2 (en) | Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent | |
| EP1746971A1 (en) | Dermatological composition for the treatment of pigmentary disorders of the skin | |
| EP1566168B1 (en) | Dermo-cosmetic compositions for depigmenting and use of it | |
| EP1019017B1 (en) | Association of phenol derivatives with extract of iridaceae family for lightening the skin and superficial body growth and composition containing same | |
| FR2946249A1 (en) | DEPIGMENTING TOPICAL COMPOSITIONS AND USES THEREOF. | |
| WO2007066041A2 (en) | Skin depigmentation composition containing a naphthonic acid derivative | |
| WO2006103352A1 (en) | Use of compounds inducing synthesis of sirt proteins in or for preparing a cosmetic or pharmaceutical compositions | |
| EP1755542A1 (en) | Mequinol-based dermatological depigmenting composition | |
| CA2511901A1 (en) | Cosmetic composition for greasy skin care, containing a carboxylic fatty acid or a derivative thereof | |
| FR3132638A1 (en) | Use of rhamnolipid(s) to prevent staining of cutaneous blackheads | |
| FR2788693A1 (en) | Use of unfermented honey as an agent for depigmenting and/or lightening the skin, body hair or head hair and/or for treating liver spots | |
| EP3995131A1 (en) | Composition for the treatment of rosacea and/or telangiectasia | |
| WO2002005779A1 (en) | Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2005771145 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2564104 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007512291 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005771145 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11596356 Country of ref document: US |